Clinical Trials Browser

Phase 2 × KD025 × Clear all

NCT03640481 2024-12-12

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Phase 2 Terminated

159 enrolled 25 charts 1 FDA

Bronchiolitis Obliterans Syndrome